Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial.

Naimi RM, Hvistendahl M, Enevoldsen LH, Madsen JL, Fuglsang S, Poulsen SS, Kissow H, Pedersen J, Nerup N, Ambrus R, Achiam MP, Svendsen LB and 8 more

Show all authors

Holst JJ, Hartmann B, Hansen SH, Dragsted LO, Steensberg A, Mouritzen U, Hansen MB, Jeppesen PB

The lancet. Gastroenterology & hepatology15 Mar 2019Cited by 60 (Europe PMC)

PMID30880176DOI10.1016/s2468-1253(19)30077-9PepBankPUB-30880176

Publisher page PubMedAsk about this study

Jump to 22 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study22

22 results from studies that gave the peptide. 22 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with short bowel syndrome, glepaglutide reduced adjusted mean faecal output by 592 g/day from baseline (p=0·002).
In plain wordsIn adults with short bowel syndrome, glepaglutide reduced faecal output from baseline.
Peptide
Glepaglutide
Outcome
DecreaseFaecal wet weight output
Study
n: not reported in source
Comparator
Baseline
Analysis
Primary
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
1 mg daily · subcutaneous · 3 weeksAs given in this study (human).
Measurements
Change in faecal wet weight output
−592 g/day
1 mg glepaglutide, adjusted mean change from baseline
Source sentences
Summary
Treatment with 1 mg and 10 mg glepaglutide changed the adjusted mean faecal output by -592 g/day (95% CI -913 to -272; p=0·002) and -833 g/day (-1152 to -515; p=0·0002) from baseline, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients received daily subcutaneous injections of the first assigned dose of glepaglutide for 3 weeks, followed by a washout period of 4-8 weeks, and then the second dose of glepaglutide for 3 weeks.
Report a problemFND-3088017601
02HumanRandomized controlled trialEfficacy outcome
In adults with short bowel syndrome, glepaglutide reduced adjusted mean faecal output by 833 g/day from baseline (p=0·0002).
In plain wordsIn adults with short bowel syndrome, glepaglutide reduced faecal output from baseline.
Peptide
Glepaglutide
Outcome
DecreaseFaecal wet weight output
Study
n: not reported in source
Comparator
Baseline
Analysis
Primary
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
10 mg daily · subcutaneous · 3 weeksAs given in this study (human).
Measurements
Change in faecal wet weight output
−833 g/day
10 mg glepaglutide, adjusted mean change from baseline
Source sentences
Summary
Treatment with 1 mg and 10 mg glepaglutide changed the adjusted mean faecal output by -592 g/day (95% CI -913 to -272; p=0·002) and -833 g/day (-1152 to -515; p=0·0002) from baseline, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients received daily subcutaneous injections of the first assigned dose of glepaglutide for 3 weeks, followed by a washout period of 4-8 weeks, and then the second dose of glepaglutide for 3 weeks.
Report a problemFND-3088017602
03HumanRandomized controlled trialEfficacy outcome
In adults with short bowel syndrome, faecal output did not change from baseline with 0·1 mg glepaglutide.
In plain wordsIn adults with short bowel syndrome, faecal output did not change from baseline with 0·1 mg glepaglutide.
Peptide
Glepaglutide
Outcome
No significant changeFaecal wet weight output
Study
n: not reported in source
Comparator
Baseline
Analysis
Primary
Outcome group
Intestinal growth and absorption · Gastrointestinal
Studied dose
0·1 mg daily · subcutaneous · 3 weeksAs given in this study (human).
Source sentences
Summary
No changes were observed with 0·1 mg glepaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Treatment with 1 mg and 10 mg glepaglutide changed the adjusted mean faecal output by -592 g/day (95% CI -913 to -272; p=0·002) and -833 g/day (-1152 to -515; p=0·0002) from baseline, respectively.
Summary · context
Patients received daily subcutaneous injections of the first assigned dose of glepaglutide for 3 weeks, followed by a washout period of 4-8 weeks, and then the second dose of glepaglutide for 3 weeks.
Report a problemFND-3088017603
04HumanRandomized controlled trialSafety outcome
In adults with short bowel syndrome, treatment-related stoma complications occurred in 13 patients (72%) receiving glepaglutide.
In plain wordsIn adults with short bowel syndrome, treatment-related stoma complications occurred in 72% of patients receiving glepaglutide.
Peptide
Glepaglutide
Outcome
Not applicableStoma complications
Study
n = 18
Outcome group
Adverse events · Gastrointestinal
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Patients with treatment-related stoma complications
13 patients
all randomized patients (n=18)
Proportion with treatment-related stoma complications
72%
all randomized patients (n=18)
Source sentences
Summary
Of the 18 patients who were randomly assigned to treatment, common treatment-related adverse events were stoma complications (13 [72%] patients),
1 context sentence(design, population, supporting numbers)
Summary · context
Patients received daily subcutaneous injections of the first assigned dose of glepaglutide for 3 weeks, followed by a washout period of 4-8 weeks, and then the second dose of glepaglutide for 3 weeks.
Report a problemFND-3088017604
05HumanRandomized controlled trialSafety outcome
In adults with short bowel syndrome, treatment-related injection site reactions occurred in 11 patients (61%) receiving glepaglutide.
In plain wordsIn adults with short bowel syndrome, treatment-related injection site reactions occurred in 61% of patients receiving glepaglutide.
Peptide
Glepaglutide
Outcome
Not applicableInjection site reactions
Study
n = 18
Outcome group
Adverse events · Skin and wound
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Patients with treatment-related injection site reactions
11 patients
all randomized patients (n=18)
Proportion with treatment-related injection site reactions
61%
all randomized patients (n=18)
Source sentences
Summary
Of the 18 patients who were randomly assigned to treatment, common treatment-related adverse events were stoma complications (13 [72%] patients), injection site reactions (11 [61%]),
1 context sentence(design, population, supporting numbers)
Summary · context
Patients received daily subcutaneous injections of the first assigned dose of glepaglutide for 3 weeks, followed by a washout period of 4-8 weeks, and then the second dose of glepaglutide for 3 weeks.
Report a problemFND-3088017605
06HumanRandomized controlled trialSafety outcome
In adults with short bowel syndrome, treatment-related peripheral oedema occurred in ten patients (56%) receiving glepaglutide.
In plain wordsIn adults with short bowel syndrome, treatment-related peripheral oedema occurred in 56% of patients receiving glepaglutide.
Peptide
Glepaglutide
Outcome
Not applicablePeripheral oedema
Study
n = 18
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Patients with treatment-related peripheral oedema
10 patients
all randomized patients (n=18)
Proportion with treatment-related peripheral oedema
56%
all randomized patients (n=18)
Source sentences
Summary
Of the 18 patients who were randomly assigned to treatment, common treatment-related adverse events were stoma complications (13 [72%] patients), injection site reactions (11 [61%]), peripheral oedema (ten [56%]),
1 context sentence(design, population, supporting numbers)
Summary · context
Patients received daily subcutaneous injections of the first assigned dose of glepaglutide for 3 weeks, followed by a washout period of 4-8 weeks, and then the second dose of glepaglutide for 3 weeks.
Report a problemFND-3088017606
07HumanRandomized controlled trialSafety outcome
In adults with short bowel syndrome, treatment-related nausea occurred in eight patients (44%) receiving glepaglutide.
In plain wordsIn adults with short bowel syndrome, treatment-related nausea occurred in 44% of patients receiving glepaglutide.
Peptide
Glepaglutide
Outcome
Not applicableNausea
Study
n = 18
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Patients with treatment-related nausea
8 patients
treatment-related, adults with short bowel syndrome (n=18)
Proportion of patients with treatment-related nausea
44%
treatment-related, adults with short bowel syndrome (n=18)
Source sentences
Summary
nausea and abdominal pain (eight [44%] each),
1 context sentence(design, population, supporting numbers)
Summary · context
Patients received daily subcutaneous injections of the first assigned dose of glepaglutide for 3 weeks, followed by a washout period of 4-8 weeks, and then the second dose of glepaglutide for 3 weeks.
Report a problemFND-3088017607
08HumanRandomized controlled trialSafety outcome
In adults with short bowel syndrome, treatment-related abdominal pain occurred in eight patients (44%) receiving glepaglutide.
In plain wordsIn adults with short bowel syndrome, treatment-related abdominal pain occurred in 44% of patients receiving glepaglutide.
Peptide
Glepaglutide
Outcome
Not applicableAbdominal pain
Study
n = 18
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Patients with treatment-related abdominal pain
8 patients
treatment-related, adults with short bowel syndrome (n=18)
Proportion of patients with treatment-related abdominal pain
44%
treatment-related, adults with short bowel syndrome (n=18)
Source sentences
Summary
nausea and abdominal pain (eight [44%] each),
1 context sentence(design, population, supporting numbers)
Summary · context
Patients received daily subcutaneous injections of the first assigned dose of glepaglutide for 3 weeks, followed by a washout period of 4-8 weeks, and then the second dose of glepaglutide for 3 weeks.
Report a problemFND-3088017608
09HumanRandomized controlled trialSafety outcome
In adults with short bowel syndrome, treatment-related polyuria occurred in six patients (33%) receiving glepaglutide.
In plain wordsIn adults with short bowel syndrome, treatment-related polyuria occurred in 33% of patients receiving glepaglutide.
Peptide
Glepaglutide
Outcome
Not applicablePolyuria
Study
n = 18
Outcome group
Adverse events · Kidney and urinary
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Patients with treatment-related polyuria
6 patients
treatment-related, adults with short bowel syndrome (n=18)
Proportion of patients with treatment-related polyuria
33%
treatment-related, adults with short bowel syndrome (n=18)
Source sentences
Summary
polyuria and fatigue (six [33%] each),
1 context sentence(design, population, supporting numbers)
Summary · context
Patients received daily subcutaneous injections of the first assigned dose of glepaglutide for 3 weeks, followed by a washout period of 4-8 weeks, and then the second dose of glepaglutide for 3 weeks.
Report a problemFND-3088017609
10HumanRandomized controlled trialSafety outcome
In adults with short bowel syndrome, treatment-related fatigue occurred in six patients (33%) receiving glepaglutide.
In plain wordsIn adults with short bowel syndrome, treatment-related fatigue occurred in 33% of patients receiving glepaglutide.
Peptide
Glepaglutide
Outcome
Not applicableFatigue
Study
n = 18
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Patients with treatment-related fatigue
6 patients
treatment-related, adults with short bowel syndrome (n=18)
Proportion of patients with treatment-related fatigue
33%
treatment-related, adults with short bowel syndrome (n=18)
Source sentences
Summary
polyuria and fatigue (six [33%] each),
1 context sentence(design, population, supporting numbers)
Summary · context
Patients received daily subcutaneous injections of the first assigned dose of glepaglutide for 3 weeks, followed by a washout period of 4-8 weeks, and then the second dose of glepaglutide for 3 weeks.
Report a problemFND-3088017610
11HumanRandomized controlled trialSafety outcome
In adults with short bowel syndrome, treatment-related abdominal distention occurred in five patients (28%) receiving glepaglutide.
In plain wordsIn adults with short bowel syndrome, treatment-related abdominal distention occurred in 28% of patients receiving glepaglutide.
Peptide
Glepaglutide
Outcome
Not applicableAbdominal distention
Study
n = 18
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Patients with treatment-related abdominal distention
5 patients
treatment-related, adults with short bowel syndrome (n=18)
Proportion of patients with treatment-related abdominal distention
28%
treatment-related, adults with short bowel syndrome (n=18)
Source sentences
Summary
abdominal distention, vomiting, and dizziness (five [28%] each);
1 context sentence(design, population, supporting numbers)
Summary · context
Patients received daily subcutaneous injections of the first assigned dose of glepaglutide for 3 weeks, followed by a washout period of 4-8 weeks, and then the second dose of glepaglutide for 3 weeks.
Report a problemFND-3088017611
12HumanRandomized controlled trialSafety outcome
In adults with short bowel syndrome, treatment-related vomiting occurred in five patients (28%) receiving glepaglutide.
In plain wordsIn adults with short bowel syndrome, treatment-related vomiting occurred in 28% of patients receiving glepaglutide.
Peptide
Glepaglutide
Outcome
Not applicableVomiting
Study
n = 18
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Patients with treatment-related vomiting
5 patients
treatment-related, adults with short bowel syndrome (n=18)
Proportion of patients with treatment-related vomiting
28%
treatment-related, adults with short bowel syndrome (n=18)
Source sentences
Summary
abdominal distention, vomiting, and dizziness (five [28%] each);
1 context sentence(design, population, supporting numbers)
Summary · context
Patients received daily subcutaneous injections of the first assigned dose of glepaglutide for 3 weeks, followed by a washout period of 4-8 weeks, and then the second dose of glepaglutide for 3 weeks.
Report a problemFND-3088017612
13HumanRandomized controlled trialSafety outcome
In adults with short bowel syndrome, treatment-related dizziness occurred in five patients (28%) receiving glepaglutide.
In plain wordsIn adults with short bowel syndrome, treatment-related dizziness occurred in 28% of patients receiving glepaglutide.
Peptide
Glepaglutide
Outcome
Not applicableDizziness
Study
n = 18
Outcome group
Adverse events · Nervous system and cognition
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Patients with treatment-related dizziness
5 patients
treatment-related, adults with short bowel syndrome (n=18)
Proportion of patients with treatment-related dizziness
28%
treatment-related, adults with short bowel syndrome (n=18)
Source sentences
Summary
abdominal distention, vomiting, and dizziness (five [28%] each);
1 context sentence(design, population, supporting numbers)
Summary · context
Patients received daily subcutaneous injections of the first assigned dose of glepaglutide for 3 weeks, followed by a washout period of 4-8 weeks, and then the second dose of glepaglutide for 3 weeks.
Report a problemFND-3088017613
14HumanRandomized controlled trialSafety outcome
In adults with short bowel syndrome, treatment-related cough occurred in four patients (22%) receiving glepaglutide.
In plain wordsIn adults with short bowel syndrome, treatment-related cough occurred in 22% of patients receiving glepaglutide.
Peptide
Glepaglutide
Outcome
Not applicableCough
Study
n = 18
Outcome group
Adverse events · Respiratory
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Patients with treatment-related cough
4 patients
treatment-related, adults with short bowel syndrome (n=18)
Proportion of patients with treatment-related cough
22%
treatment-related, adults with short bowel syndrome (n=18)
Source sentences
Summary
cough and decreased appetite (four [22%] each).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients received daily subcutaneous injections of the first assigned dose of glepaglutide for 3 weeks, followed by a washout period of 4-8 weeks, and then the second dose of glepaglutide for 3 weeks.
Report a problemFND-3088017614
15HumanRandomized controlled trialSafety outcome
In adults with short bowel syndrome, treatment-related decreased appetite occurred in four patients (22%) receiving glepaglutide.
In plain wordsIn adults with short bowel syndrome, treatment-related decreased appetite occurred in 22% of patients receiving glepaglutide.
Peptide
Glepaglutide
Outcome
Not applicableDecreased appetite
Study
n = 18
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Patients with treatment-related decreased appetite
4 patients
treatment-related, adults with short bowel syndrome (n=18)
Proportion of patients with treatment-related decreased appetite
22%
treatment-related, adults with short bowel syndrome (n=18)
Source sentences
Summary
cough and decreased appetite (four [22%] each).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients received daily subcutaneous injections of the first assigned dose of glepaglutide for 3 weeks, followed by a washout period of 4-8 weeks, and then the second dose of glepaglutide for 3 weeks.
Report a problemFND-3088017615
16HumanRandomized controlled trialSafety outcome
In adults with short bowel syndrome receiving glepaglutide, no patients died during the trial.
In plain wordsIn adults with short bowel syndrome receiving glepaglutide, no patients died during the trial.
Peptide
Glepaglutide
Outcome
Not applicableDeaths
Study
n = 18
Outcome group
Mortality · Whole body
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
No patients died during the trial.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients received daily subcutaneous injections of the first assigned dose of glepaglutide for 3 weeks, followed by a washout period of 4-8 weeks, and then the second dose of glepaglutide for 3 weeks.
Report a problemFND-3088017622
17HumanRandomized controlled trialSafety outcome
In adults with short bowel syndrome, related or possibly related serious adverse events occurred in two patients receiving 0·1 mg glepaglutide.
In plain wordsIn adults with short bowel syndrome, two patients receiving 0·1 mg glepaglutide experienced related or possibly related serious adverse events.
Peptide
Glepaglutide
Outcome
Not applicableRelated or possibly related serious adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
0·1 mg daily · subcutaneous · 3 weeksAs given in this study (human).
Measurements
Patients with related or possibly related serious adverse events
2 patients
glepaglutide 0·1 mg dose group
Source sentences
Summary
Related or possibly related serious adverse events were reported in two patients in the 0·1 mg dose group and two patients in the 10 mg dose group.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients received daily subcutaneous injections of the first assigned dose of glepaglutide for 3 weeks, followed by a washout period of 4-8 weeks, and then the second dose of glepaglutide for 3 weeks.
Report a problemFND-3088017616
18HumanRandomized controlled trialSafety outcome
In adults with short bowel syndrome, related or possibly related serious adverse events occurred in two patients receiving 10 mg glepaglutide.
In plain wordsIn adults with short bowel syndrome, two patients receiving 10 mg glepaglutide experienced related or possibly related serious adverse events.
Peptide
Glepaglutide
Outcome
Not applicableRelated or possibly related serious adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
10 mg daily · subcutaneous · 3 weeksAs given in this study (human).
Measurements
Patients with related or possibly related serious adverse events
2 patients
glepaglutide 10 mg dose group
Source sentences
Summary
Related or possibly related serious adverse events were reported in two patients in the 0·1 mg dose group and two patients in the 10 mg dose group.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients received daily subcutaneous injections of the first assigned dose of glepaglutide for 3 weeks, followed by a washout period of 4-8 weeks, and then the second dose of glepaglutide for 3 weeks.
Report a problemFND-3088017617
19HumanRandomized controlled trialSafety outcome
In adults with short bowel syndrome receiving glepaglutide, related or possibly related serious adverse events included abdominal pain.
In plain wordsIn adults with short bowel syndrome receiving glepaglutide, related or possibly related serious adverse events included abdominal pain.
Peptide
Glepaglutide
Outcome
Not applicableSerious abdominal pain
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
These events included abdominal pain, stoma obstruction, catheter-related sepsis, and infection of unknown origin.
2 context sentences(design, population, supporting numbers)
Summary · context
Related or possibly related serious adverse events were reported in two patients in the 0·1 mg dose group and two patients in the 10 mg dose group.
Summary · context
Patients received daily subcutaneous injections of the first assigned dose of glepaglutide for 3 weeks, followed by a washout period of 4-8 weeks, and then the second dose of glepaglutide for 3 weeks.
Report a problemFND-3088017618
20HumanRandomized controlled trialSafety outcome
In adults with short bowel syndrome receiving glepaglutide, related or possibly related serious adverse events included stoma obstruction.
In plain wordsIn adults with short bowel syndrome receiving glepaglutide, related or possibly related serious adverse events included stoma obstruction.
Peptide
Glepaglutide
Outcome
Not applicableSerious stoma obstruction
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
These events included abdominal pain, stoma obstruction, catheter-related sepsis, and infection of unknown origin.
2 context sentences(design, population, supporting numbers)
Summary · context
Related or possibly related serious adverse events were reported in two patients in the 0·1 mg dose group and two patients in the 10 mg dose group.
Summary · context
Patients received daily subcutaneous injections of the first assigned dose of glepaglutide for 3 weeks, followed by a washout period of 4-8 weeks, and then the second dose of glepaglutide for 3 weeks.
Report a problemFND-3088017619
21HumanRandomized controlled trialSafety outcome
In adults with short bowel syndrome receiving glepaglutide, related or possibly related serious adverse events included catheter-related sepsis.
In plain wordsIn adults with short bowel syndrome receiving glepaglutide, related or possibly related serious adverse events included catheter-related sepsis.
Peptide
Glepaglutide
Outcome
Not applicableSerious catheter-related sepsis
Study
n: not reported in source
Outcome group
Adverse events · Infection
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
These events included abdominal pain, stoma obstruction, catheter-related sepsis, and infection of unknown origin.
2 context sentences(design, population, supporting numbers)
Summary · context
Related or possibly related serious adverse events were reported in two patients in the 0·1 mg dose group and two patients in the 10 mg dose group.
Summary · context
Patients received daily subcutaneous injections of the first assigned dose of glepaglutide for 3 weeks, followed by a washout period of 4-8 weeks, and then the second dose of glepaglutide for 3 weeks.
Report a problemFND-3088017620
22HumanRandomized controlled trialSafety outcome
In adults with short bowel syndrome receiving glepaglutide, related or possibly related serious adverse events included infection of unknown origin.
In plain wordsIn adults with short bowel syndrome receiving glepaglutide, related or possibly related serious adverse events included infection of unknown origin.
Peptide
Glepaglutide
Outcome
Not applicableSerious infection of unknown origin
Study
n: not reported in source
Outcome group
Adverse events · Infection
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
These events included abdominal pain, stoma obstruction, catheter-related sepsis, and infection of unknown origin.
2 context sentences(design, population, supporting numbers)
Summary · context
Related or possibly related serious adverse events were reported in two patients in the 0·1 mg dose group and two patients in the 10 mg dose group.
Summary · context
Patients received daily subcutaneous injections of the first assigned dose of glepaglutide for 3 weeks, followed by a washout period of 4-8 weeks, and then the second dose of glepaglutide for 3 weeks.
Report a problemFND-3088017621

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT02690025

A Phase 2 Trial Testing ZP1848 in Patients With SBS

Zealand Pharman = 18Feb 2016 to May 2017

Short Bowel Syndrome

Trial page ClinicalTrials.govUpdated 21 Jun 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.